Adam Fine
Co-Founder, General Partner & CEO @ Windham Venture Partners
New York, United States
Adam Fine is a co-founder and CEO of Windham Venture Partners. Adam is currently Director at GlySens, CuraSeal and HelpAround, Board Observer to SpineView, MC10, Holaira and VytronUS. Adam is a mentor in Blueprint Health, a healthcare IT accelerator in NYC. Prior to Windham, Adam was VP & GM at I-many, Inc., an enterprise software company.Prior to joining I-many, Adam was a New Business Development Analyst at Cordis Corporation, a Johnson & Johnson company focused on interventional vascular devices such as stents. In that capacity, Adam worked on a range of licenses, acquisitions, divestments, as well as strategic investments with Johnson & Johnson Development Corporation (JJDC), J&J’s strategic venture arm. Prior to J&J, Adam was a research analyst at Coopers & Lybrand’s Integrated Healthcare Consulting practice.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Adam Fine invests in
Stages Adam Fine invests in
Countries Adam Fine invests in
Investment Focus
Industry
- Health Care 5 (63%)
- Medical 3 (38%)
- Wellness 3 (38%)
- Fitness 2 (25%)
- Retail 1 (13%)
Stage
- Series A 2 (25%)
- Series B 1 (13%)
- Series C 1 (13%)
- Series D 1 (13%)
- Funding Round 1 (13%)
Country
- United States 4 (50%)
- Israel 2 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Fore Biotherapeutics
|
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M / Series D / Jul 07, 2026 | |
TailorMed
|
TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data setto create actionable insights. | $27.5M / Series B / Nov 21, 2024 | |
Valera Health
|
Founded in 2015, Valera Health combines digital technology and data science with human touch to deliver best inclass clinical services to patients with mild to severe mental health conditions including depression to schizophrenia. With a focus on outcomes and servicing hard to reach populations, Valera Health is redefining high-performing mentalhealthcare. | $45M / Venture - Series Unknown / Oct 07, 2022 | |
|
Valera Health
|
Founded in 2015, Valera Health combines digital technology and data science with human touch to deliver best inclass clinical services to patients with mild to severe mental health conditions including depression to schizophrenia. With a focus on outcomes and servicing hard to reach populations, Valera Health is redefining high-performing mentalhealthcare. | $15M / Venture - Series Unknown / Nov 04, 2021 | |
SubjectWell
|
SubjectWell is the risk-free clinical trials marketplace for patient recruitment | $10M / Series A / Jun 17, 2019 | |
|
Fore Biotherapeutics
|
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $6M / Apr 30, 2018 | |
Coravin
|
Coravin offers a proprietary wine access technology that does not disturb a wine's aging process even after the cork is removed. The company's technology allows them to pour and enjoy fine wines without disturbing the natural aging process- or the process to commit to the whole bottle. Its first product, the Coravin Wine PreservationOpener, pours wine without removing the cork from the bottle.Coravin was founded in 2011 and is headquartered in Bedford, Massachusetts, United States. | $13.6M / Series C / Jun 18, 2015 | |
Welldoc
|
WellDoc is developing the next generation of technology solutions to support chronic disease management. Its mission is to improve the lives of people with chronic diseases they fulfill their mission by integrating clinical, behavioral, and motivational applications with everyday technologies, like the internet and cell phone, to engage patientsand healthcare providers in ways that dramatically improve outcomes and significantly reduce healthcare costs.It was founded in 2005 and headquartered in Columbia, Maryland. | Series A / Jan 10, 2014 |
Co-Investors
About Windham Venture Partners
Founded in 2006, Windham is a New York City based venture capital firm focused on healthcare, with a particular emphasis on medical technology (devices and diagnostics) and digital health (the intersection of biology, genomics, and information technology). Windham seeks to invest in and partner with companies that are commercializinggame-changing technologies to serve unmet needs in order to improve the lives of large numbers of patients and yield robust returns for its investors. For more information visit: www.windhamvp.com
Windham Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Adam Fine
Co-Founder, General Partner & CEO
|
|||
Lorne Taichman
Director of Science & Technology
|
|||
Roger Fine
Co-Founder & Chairman; Chairman of the Robert Wood Johnson Foundation
|
|||
David J. Kereiakes
Managing Partner
|
|||
Joe Proto
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Adam Fine invest in?
Adam Fine invests primarily in Health Care, Medical and Wellness startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Adam Fine last invest?
The most recent investment recorded for Adam Fine closed in Jul 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
